cbdMD shares surge 53.70% intraday after launching integrated regulatory science program and acquiring Bluebird Botanicals for 10% revenue growth.

cbdMD surged 53.70% intraday following the announcement of a strategic regulatory science initiative and the integration of Bluebird Botanicals' assets. The company acquired Bluebird’s assets, expected to drive 10% revenue growth, and launched a program to consolidate its scientific and regulatory capabilities, including leveraging Bluebird’s self-affirmed GRAS status for full-spectrum hemp extracts. The initiative aims to strengthen regulatory compliance and market positioning amid evolving federal frameworks, as highlighted by CEO Ronan Kennedy. These developments, coupled with the acquisition of Gaia Botanicals’ assets and the expansion of cbdMD’s product portfolio, signaled growth potential and operational expansion, likely driving the sharp intraday rally.